These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 19667555)

  • 21. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
    Harada S; Ishii Y; Yamaguchi K
    Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended spectrum beta lactamase--mediated resistance among isolates of family Enterobacteriaceae.
    Deep ; Arora U
    Indian J Pathol Microbiol; 2007 Apr; 50(2):458-61. PubMed ID: 17883109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First detection of plasmid-mediated, quinolone resistance determinants qnrA, qnrB, qnrS and aac(6')-Ib-cr in extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Budapest, Hungary.
    Szabó D; Kocsis B; Rókusz L; Szentandrássy J; Katona K; Kristóf K; Nagy K
    J Antimicrob Chemother; 2008 Sep; 62(3):630-2. PubMed ID: 18477707
    [No Abstract]   [Full Text] [Related]  

  • 25. Appearance of aac(6')-Ib-cr gene among extended-spectrum beta-lactamase-producing Enterobacteriaceae in a French hospital.
    Fihman V; Lartigue MF; Jacquier H; Meunier F; Schnepf N; Raskine L; Riahi J; Sanson-le Pors MJ; Berçot B
    J Infect; 2008 Jun; 56(6):454-9. PubMed ID: 18440645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-spectrum beta-lactamases and the permeability barrier.
    Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():82-9. PubMed ID: 18154531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates.
    Spanu T; Sanguinetti M; Tumbarello M; D'Inzeo T; Fiori B; Posteraro B; Santangelo R; Cauda R; Fadda G
    J Clin Microbiol; 2006 Sep; 44(9):3257-62. PubMed ID: 16954257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
    Hallgren H; Gustafsson I; Ripa T
    Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531
    [No Abstract]   [Full Text] [Related]  

  • 29. [Epidemiology of Enterobacteriaceae producing extended-spectrum beta-lactamase in Grasse Hospital (2005-2008)].
    Leotard S; Negrin N
    Pathol Biol (Paris); 2010 Feb; 58(1):35-8. PubMed ID: 19864086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
    Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
    Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
    [No Abstract]   [Full Text] [Related]  

  • 31. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.
    Schwaber MJ; Navon-Venezia S; Schwartz D; Carmeli Y
    Antimicrob Agents Chemother; 2005 May; 49(5):2137-9. PubMed ID: 15855548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community.
    Pitout JD; Nordmann P; Laupland KB; Poirel L
    J Antimicrob Chemother; 2005 Jul; 56(1):52-9. PubMed ID: 15917288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases.
    Endimiani A; Paterson DL
    Semin Respir Crit Care Med; 2007 Dec; 28(6):646-55. PubMed ID: 18095228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
    Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
    Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
    Muratani T; Matsumoto T
    Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recognition and management of extended spectrum beta lactamase producing organisms (ESBL).
    Fircanis S; McKay M
    Med Health R I; 2010 May; 93(5):161-2. PubMed ID: 20533728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and risk factors for colonisation with extended spectrum beta-lactamase producing enterobacteriacae vis-à-vis usage of antimicrobials.
    Sarma JB; Ahmed GU
    Indian J Med Microbiol; 2010; 28(3):217-20. PubMed ID: 20644309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?
    Harris PN; Ferguson JK
    Int J Antimicrob Agents; 2012 Oct; 40(4):297-305. PubMed ID: 22824371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-lactamases in Enterobacteriaceae infections in children.
    Moxon CA; Paulus S
    J Infect; 2016 Jul; 72 Suppl():S41-9. PubMed ID: 27180312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and clonality of extended-spectrum beta-lactamases in Asia.
    Hawkey PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():159-65. PubMed ID: 18154540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.